FibroBiologics, Inc. (FBLG) Financial Statements (2026 and earlier)

Company Profile

Business Address 9350 KIRBY DRIVE
HOUSTON, TX 77054
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,89413,9859,163
Cash and cash equivalent4,89413,9859,163
Prepaid expense1,45522536
Other current assets 1816
Total current assets:6,34914,2289,215
Noncurrent Assets
Operating lease, right-of-use asset2,3801,3931,809
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization842824797
Other undisclosed noncurrent assets48  
Total noncurrent assets:3,2702,2172,606
TOTAL ASSETS:9,61916,44511,821
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9452,6971,444
Accrued liabilities 250  
Other undisclosed accounts payable and accrued liabilities6952,6971,444
Debt 9,168 
Other undisclosed current liabilities8148617,739
Total current liabilities:1,75912,7269,183
Noncurrent Liabilities
Liabilities, other than long-term debt1,7049841,385
Operating lease, liability1,7049841,385
Total noncurrent liabilities:1,7049841,385
Total liabilities:3,46313,71010,568
Equity
Equity, attributable to parent, including:6,1562,7351,253
Common stock1  
Additional paid in capital60,31938,25325,609
Accumulated deficit(54,164)(35,518)(24,357)
Other undisclosed equity, attributable to parent   1
Total equity:6,1562,7351,253
TOTAL LIABILITIES AND EQUITY:9,61916,44511,821

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
Revenues352  
Gain (loss) on disposition of assets for financial service operations352(460) 
Gross profit:352  
Operating expenses(16,649)(13,737)(8,889)
Other undisclosed operating income (loss)(352)460 
Operating loss:(16,649)(13,737)(8,889)
Nonoperating income (expense)(1,997)283(213)
Investment income, nonoperating247251 
Other nonoperating income (expense)(619)32 
Interest and debt expense(204)(20)(147)
Other undisclosed loss from continuing operations before equity method investments, income taxes   
Net loss:(18,850)(13,474)(9,249)
Other undisclosed net income (loss) attributable to parent2042,313(7,236)
Net loss attributable to parent:(18,646)(11,161)(16,485)
Other undisclosed net loss available to common stockholders, basic   (2,573)
Net loss available to common stockholders, diluted:(18,646)(11,161)(19,058)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
Net loss:(18,850)(13,474)(9,249)
Comprehensive loss, net of tax, attributable to parent:(18,850)(13,474)(9,249)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: